FNCHQ · Finch Therapeutics Group, Inc.
$10.35
+0.00 (+0.00%)
At close · Sep 3
Going-concern doubt
— flagged Aug 13, 2024
Substantial doubt about the company's ability to continue as a going concern.
“due to the consideration of certain qualitative factors, including the Company's recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2024
Market Cap
$16.62M
Shares
1.61M
FNCHQ metrics
50 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$10.35
Market cap
$16.62M
Price action
19 metricsPrice change (1W)
+1.5%
Price change (30D)
+2.5%
Price change (3M)
—
Price change (6M)
-21.9%
Price change (YTD)
-23.3%
Price change (1Y)
-20.4%
Trailing year
Price change (5Y)
—
52-week high
$14.56
52-week low
$6.21
Change from 52-week high
-28.9%
Change from 52-week low
+66.7%
Annualized volatility
77.5%
Beta
0.1
RSI (14D)
59.6
Price vs SMA 50
+11.9%
Price vs SMA 200
-10.4%
Avg volume (3M)
2,431
Relative volume
4.1
Average dollar volume
$23,517
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
1.61M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.2
reciprocal yield 85.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-85.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-121.1×
EV / revenue historical average (5Y)
-121.1×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2022-05-16
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$19.50M
Net income (TTM)
−$14.17M
Trailing 12 months
Diluted EPS (TTM)
$-8.49
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-87.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.1%
Year over year · more shares
Revenue CAGR (3Y)
-76.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-99.6%
Return on assets
-31.1%
Debt / equity
—
Current ratio
3.9
EBITDA (TTM)
−$19.32M
Free cash flow (TTM)
—
Quick ratio
3.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$16.04M
Total assets
$45.58M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$18.05M
Capital expenditures (TTM)
—
R&D (TTM)
$0
SG&A (TTM)
—
Stock compensation (TTM)
$492,000
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
24 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged